Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dalgarno

Showing results (451-460 of 479) with videos related to

Pageof 48
Sort By:
Chemical Biology & Drug Design|February 24, 2006
Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compoundsDavid Dalgarno, Thilo Stehle, Surinder Narula, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2001
A novel phosphotyrosine mimetic 4'-carboxymethyloxy-3'-phosphonophenylalanine (Cpp): exploitation in the design of nonpeptide inhibitors of pp60(Src) SH2 domainN Kawahata, M G Yang, G P Luke, et al.
Canadian Medical Education Journal|July 12, 2026
Rethinking how we educate our future physicians: the Queen's-Lakeridge Health Medical Degree Family Medicine program: an innovative approach to medical educationEugenia Piliotis, Jennifer Turnnidge, Cailie S McGuire, et al.
Blood|July 17, 2004
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CMLThomas O'Hare, Roy Pollock, Eric P Stoffregen, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2008
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitorsYihan Wang, William C Shakespeare, Wei-Sheng Huang, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseasesYihan Wang, Chester A Metcalf, William C Shakespeare, et al.
Science (New York, N.Y.)|November 23, 1979
Extreme ultraviolet observations from voyager 2 encounter with jupiterB R Sandel, D E Shemansky, A L Broadfoot, et al.
Science (New York, N.Y.)|June 1, 1979
Extreme ultraviolet observations from voyager 1 encounter with jupiterA L Broadfoot, M J Belton, P Z Takacs, et al.
Cancer Research|September 5, 2006
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinomaLiz Y Han, Charles N Landen, Jose G Trevino, et al.
Blood Advances|November 8, 2019
Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cellsTomasz Sewastianik, Maria Luisa Guerrera, Keith Adler, et al.
Pageof 48

Showing results (451-460 of 479) with videos related to

Sort By:
Pageof 48
Chemical Biology & Drug Design|February 24, 2006
Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compoundsDavid Dalgarno, Thilo Stehle, Surinder Narula, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2001
A novel phosphotyrosine mimetic 4'-carboxymethyloxy-3'-phosphonophenylalanine (Cpp): exploitation in the design of nonpeptide inhibitors of pp60(Src) SH2 domainN Kawahata, M G Yang, G P Luke, et al.
Canadian Medical Education Journal|July 12, 2026
Rethinking how we educate our future physicians: the Queen's-Lakeridge Health Medical Degree Family Medicine program: an innovative approach to medical educationEugenia Piliotis, Jennifer Turnnidge, Cailie S McGuire, et al.
Blood|July 17, 2004
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CMLThomas O'Hare, Roy Pollock, Eric P Stoffregen, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2008
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitorsYihan Wang, William C Shakespeare, Wei-Sheng Huang, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseasesYihan Wang, Chester A Metcalf, William C Shakespeare, et al.
Science (New York, N.Y.)|November 23, 1979
Extreme ultraviolet observations from voyager 2 encounter with jupiterB R Sandel, D E Shemansky, A L Broadfoot, et al.
Science (New York, N.Y.)|June 1, 1979
Extreme ultraviolet observations from voyager 1 encounter with jupiterA L Broadfoot, M J Belton, P Z Takacs, et al.
Cancer Research|September 5, 2006
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinomaLiz Y Han, Charles N Landen, Jose G Trevino, et al.
Blood Advances|November 8, 2019
Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cellsTomasz Sewastianik, Maria Luisa Guerrera, Keith Adler, et al.
Pageof 48